Healthcare provider profile · identity verified

Matthew Blake Webber, ARNP

Nurse Practitioner · GIG HARBOR, WA · NPI 1679011654

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	288	94
Lisinopril	Lisinopril	208	65
Omeprazole	Omeprazole	140	51
Amlodipine Besylate	Amlodipine Besylate	139	51
Losartan Potassium	Losartan Potassium	135	46
Levothyroxine Sodium	Levothyroxine Sodium	130	41
Tamsulosin Hcl	Tamsulosin Hcl	116	36
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	111	19
Gabapentin	Gabapentin	103	39
Metoprolol Succinate	Metoprolol Succinate	82	26
Simvastatin	Simvastatin	74	21
Metformin Hcl	Metformin Hcl	73	27
Albuterol Sulfate Hfa	Albuterol Sulfate	71	27
Pantoprazole Sodium	Pantoprazole Sodium	66	19
Zolpidem Tartrate	Zolpidem Tartrate	66	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	61	11
Rosuvastatin Calcium	Rosuvastatin Calcium	59	22
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	57	28
Hydrochlorothiazide	Hydrochlorothiazide	55	19
Pravastatin Sodium	Pravastatin Sodium	50	17
Tramadol Hcl	Tramadol Hcl	47	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	44	13
Meloxicam	Meloxicam	44	23
Trazodone Hcl	Trazodone Hcl	44	16
Metoprolol Tartrate	Metoprolol Tartrate	43	14
Sertraline Hcl	Sertraline Hcl	40	12
Allopurinol	Allopurinol	38	12
Buspirone Hcl	Buspirone Hcl	38	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	37	suppressed
Clopidogrel	Clopidogrel Bisulfate	36	suppressed
Oxycodone Hcl	Oxycodone Hcl	36	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	35	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	34	12
Metformin Hcl Er	Metformin Hcl	34	11
Potassium Chloride	Potassium Chloride	34	suppressed
Citalopram Hbr	Citalopram Hydrobromide	32	suppressed
Carvedilol	Carvedilol	29	suppressed
Mounjaro	Tirzepatide	28	suppressed
Alprazolam	Alprazolam	27	suppressed
Xarelto	Rivaroxaban	27	suppressed
Atenolol	Atenolol	26	suppressed
Eliquis	Apixaban	24	suppressed
Jardiance	Empagliflozin	24	suppressed
Duloxetine Hcl	Duloxetine Hcl	23	suppressed
Diazepam	Diazepam	21	suppressed
Finasteride	Finasteride	21	suppressed
Montelukast Sodium	Montelukast Sodium	21	suppressed
Tizanidine Hcl	Tizanidine Hcl	21	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	21	suppressed
Furosemide	Furosemide	20	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	19	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	18	suppressed
Synthroid	Levothyroxine Sodium	18	suppressed
Azithromycin	Azithromycin	17	16
Naproxen	Naproxen	17	14
Fluticasone Propionate	Fluticasone Propionate	16	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Eszopiclone	Eszopiclone	15	suppressed
Methocarbamol	Methocarbamol	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	14
Bumetanide	Bumetanide	14	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	12
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Repatha Sureclick	Evolocumab	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	13
Aripiprazole	Aripiprazole	13	suppressed
Clonazepam	Clonazepam	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Terazosin Hcl	Terazosin Hcl	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Estradiol	Estradiol	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Lyrica	Pregabalin	12	suppressed
Pregabalin	Pregabalin	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Alendronate Sodium	Alendronate Sodium	11	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Lovastatin	Lovastatin	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Telmisartan	Telmisartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error